Now showing items 1-10 of 12
Topical microbicides - What's new?
(Lippincott Williams & Wilkins., 2013)
Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
(Wiley Online Library., 2014)
Abstract available in pdf.
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
(Oxford University Press., 2014)
The Centre for the AIDS Programme of Research in South Africa 004 (CAPRISA 004) study demonstrated that vaginally applied tenofovir gel is a promising intervention for protecting women from sexually acquiring human ...
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial.
(Lippincott Williams & Wilkins., 2012)
Objective: To assess the role of natural killer (NK) cells in HIV acquisition. Design: We conducted a nested case–control substudy to the Center for the AIDS Programme of Research in South Africa (CAPRISA004) tenofovir gel ...
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Abstract not available in pdf.
Women with pregnancies had lower adherence to 1% Tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Background: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links ...
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
(International Medical Press., 2012)
Background: Tenofovir gel, used vaginally before and after coitus, reduced women’s acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological ...
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
(American Association for the Advancement of Science., 2010)
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
(Lippincott Williams & Wilkins., 2015)
Abstract available in pdf.
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
(BioMed Central., 2014)
Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory ...